News & Events

John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer

Co-founder and Interim CEO Brian MacDonald to Serve as Senior Advisor and Director Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced

More News

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at...


read more

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...


read more